Skip to main content
. 2016 Jul 29;5(8):e003718. doi: 10.1161/JAHA.116.003718

Figure 5.

Figure 5

Antihypertrophy effect of TRPV1 antagonist in TAC‐treated mouse. A, Representative histological staining of cardiomyocytes in mice treated with vehicle control or CPZ (0.1, 0.5, or 2.5 mg/kg per day) at 8 weeks after TAC or sham surgery. Scale bar=25 μm. Analysis of cardiomyocyte cross‐sectional area (B) and ratio of heart weight normalized to body weight (C) was measured in the above groups (n=5 mice per group). *P<0.05, **P<0.01. D, Representative serial M‐model echocardiographic tracings in control, sham, vehicle, and CPZ (0.1, 0.5, or 2.5 mg/kg per day) treatment after TAC show LVIDs and LVIDd. CPZ indicates capsazepine; d, end‐diastole; D, diameter; HW/BW, heart weight/body weight ratio; LVAW, left ventricular anterior wall thickness; LVID, left ventricular internal dimension; LVPW, left ventricular posterior wall thickness; s, end‐systole; TAC, transverse aorta constriction.